ELI LILLY & Co (LLY) vs Viatris Inc (VTRS)
Side-by-side comparison from SEC filings: latest annual financials, insider activity and institutional ownership.
| Metric | LLY | VTRS |
|---|---|---|
| Sector | Health Care | Health Care |
| Latest fiscal year | FY2025 | FY2025 |
| Revenue | $65.18B | $14.3B |
| Revenue growth (YoY) | ▲ 44.7% | ▼ 3.0% |
| Net income | $20.64B | -$3.51B |
| Gross margin | 83.0% | 35.1% |
| Diluted EPS | $22.95 | $-3.00 |
| Insider net (6 mo) | −31.3K sh • 5 sells • 0 buys | −35.3K sh • 1 sells • 0 buys |
| Institutional owners | 51 | 41 |
| Institutional value held | $533.23B | $10.77B |
| Next earnings (est.) | Around Oct 29, 2026 | Around Nov 5, 2026 |
Figures from each company's SEC filings (latest reported fiscal year; fiscal calendars may differ). Next-earnings dates are estimates from historical filing patterns.
About ELI LILLY & Co (LLY)
Eli Lilly and Company, incorporated in Indiana in 1901 and tracing its roots to a drug manufacturing business founded in 1876, operates as a single-segment human pharmaceutical company focused on discovering, developing, manufacturing, and marketing… Read more →
About Viatris Inc (VTRS)
Viatris is a global healthcare company formed in November 2020 through the combination of Mylan and Pfizer's Upjohn business, with a mission to empower people worldwide to live healthier at every stage of life regardless of geography or circumstance. Read more →
Source: SEC EDGAR.